symbol,statement_type,period_end,line_item,value
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.001218
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Normalized EBITDA,-149786000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Total Unusual Items,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,2146000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,162711000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,EBITDA,-149786000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,EBIT,-151932000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Interest Income,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Interest Expense,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Interest Income,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Normalized Income,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Total Expenses,318808000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Diluted Average Shares,29465437.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Basic Average Shares,29465437.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Diluted EPS,-5.15
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Basic EPS,-5.15
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income Discontinuous Operations,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,-151747000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Tax Provision,-185000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Pretax Income,-151932000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Special Income Charges,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Other Special Charges,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Write Off,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,0.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Operating Income,-151932000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Operating Expense,156097000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Other Operating Expenses,153783000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,2146000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,2146000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Selling General And Administration,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Gross Profit,4165000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Cost Of Revenue,162711000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Total Revenue,166876000.0
LYPSAGEMS.NS,income,2025-03-31 00:00:00,Operating Revenue,166876000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.3
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Normalized EBITDA,-324343000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,2358000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,90988000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,EBITDA,-324343000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,EBIT,-326701000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Interest Income,-1000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Interest Expense,1000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Interest Income,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Normalized Income,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Total Expenses,421555000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Diluted Average Shares,29496573.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Basic Average Shares,29496573.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Diluted EPS,-11.09
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Basic EPS,-11.09
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income Discontinuous Operations,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,-327117000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Tax Provision,415000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Pretax Income,-326702000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Special Income Charges,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Other Special Charges,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Write Off,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-1000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,1000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,0.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Operating Income,-326701000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Operating Expense,330567000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Other Operating Expenses,328041000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,2358000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,2358000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Selling General And Administration,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,General And Administrative Expense,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Gross Profit,3866000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Cost Of Revenue,90988000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Total Revenue,94854000.0
LYPSAGEMS.NS,income,2024-03-31 00:00:00,Operating Revenue,94854000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.3
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Normalized EBITDA,-438217000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Total Unusual Items,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,2719000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,128535000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,EBITDA,-438217000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,EBIT,-440936000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Interest Income,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Interest Expense,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Interest Income,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Normalized Income,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Total Expenses,572871000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Diluted Average Shares,29484000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Basic Average Shares,29484000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Diluted EPS,-14.96
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Basic EPS,-14.96
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income Discontinuous Operations,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,-440972000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Tax Provision,36000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Pretax Income,-440936000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Special Income Charges,-439452000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Other Special Charges,
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Write Off,439452000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Operating Income,-440936000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Operating Expense,444336000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Other Operating Expenses,441461000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,2719000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,2719000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Selling General And Administration,1930000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,General And Administrative Expense,1930000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,0.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Gross Profit,3400000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Cost Of Revenue,128535000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Total Revenue,131935000.0
LYPSAGEMS.NS,income,2023-03-31 00:00:00,Operating Revenue,131935000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,444907.97546
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.245399
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Normalized EBITDA,-224000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Total Unusual Items,1813000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,1813000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,2730000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,136913000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,EBITDA,1589000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,EBIT,-1141000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Interest Income,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Interest Expense,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Interest Income,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Normalized Income,-2229092.02454
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Total Expenses,143194000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Diluted Average Shares,29484000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Basic Average Shares,29484000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Diluted EPS,-0.03
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Basic EPS,-0.03
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income Discontinuous Operations,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,-861000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Tax Provision,-280000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Pretax Income,-1141000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,2000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Special Income Charges,1813000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Other Special Charges,101000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Write Off,-1914000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Operating Income,-2956000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Operating Expense,6281000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Other Operating Expenses,266000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,2730000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,2730000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Selling General And Administration,1958000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,General And Administrative Expense,1958000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,0.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Gross Profit,3325000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Cost Of Revenue,136913000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Total Revenue,140238000.0
LYPSAGEMS.NS,income,2022-03-31 00:00:00,Operating Revenue,140238000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Total Unusual Items,885000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,885000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,EBITDA,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,EBIT,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Interest Income,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Interest Expense,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Interest Income,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Normalized Income,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Total Expenses,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Basic Average Shares,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Diluted EPS,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Basic EPS,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income Discontinuous Operations,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Tax Provision,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Pretax Income,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Special Income Charges,885000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Other Special Charges,-885000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Write Off,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Operating Income,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Operating Expense,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Selling General And Administration,1036000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,General And Administrative Expense,1036000.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,0.0
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Gross Profit,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Total Revenue,
LYPSAGEMS.NS,income,2021-03-31 00:00:00,Operating Revenue,
